Trial reportHaematologica2019
Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms.
Abstract readClinical Trial, Phase IClinical Trial, Phase IILetter
In one paragraph
Trial report in Haematologica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Trial
- Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML.Blood advances · 2023Trial
- Trial
- Precision oncology to overcome resistance in R/R AML in children and adults requires combinations of cytotoxic, targeted, and immunological treatments.Journal of internal medicine · 2025Review
- Treatment discontinuation due to toxicity for patients with acute myeloid leukemia receiving intensive chemotherapy.Blood neoplasia · 2025Article
- Phase 1 trial of venetoclax with cladribine, cytarabine, G-CSF, and mitoxantrone for AML and high-grade myeloid neoplasm.Blood neoplasia · 2025Article
- Efficacy and safety of mitoxantrone hydrochloride liposome-containing regimens in treating refractory/relapsed acute myeloid leukemia.Discover oncology · 2025Article
- Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed/refractory acute myeloid leukemia.Leukemia · 2025Article
- Identification of factors predicting low-risk febrile neutropenia admissions in adults with acute myeloid leukemia.Blood advances · 2024Article
- Intensive Reinduction Chemotherapy Followed by Early Allogeneic Hematopoietic Cell Transplantation for Relapsed/Refractory High-Grade Myeloid Neoplasms.Transplantation and cellular therapy · 2024Article
- Venetoclax Combined with Intensive Chemotherapy: A New Hope for Refractory and/or Relapsed Acute Myeloid Leukemia?Journal of clinical medicine · 2024Review
- Invasive fungal infections after CLAG-M/CLAG chemotherapy for acute myeloid leukemia and high-grade myeloid neoplasms.Blood advances · 2023Article
- Efficacy and toxicity of CLAG combined with pegylated liposomal doxorubicin in the treatment of refractory or relapsed acute myeloid leukemia.Cancer medicine · 2023Article
- Results from a phase I study of continuous infusion cladribine, high-dose cytarabine, and mitoxantrone for relapsed/refractory high-grade myeloid neoplasms.Leukemia & lymphoma · 2023Article
- Effectiveness of chemotherapy using bortezomib combined with homoharringtonine and cytarabine in refractory or relapsed acute myeloid leukemia: a phase II, multicenter, prospective clinical trial.Frontiers in oncology · 2023Article
- Article
- Where do we stand with radioimmunotherapy for acute myeloid leukemia?Expert opinion on biological therapy · 2022Article
- Treatment options for acute myeloid leukemia patients aged <60 years.Frontiers in oncology · 2022Review
- Adoptive immunotherapy with CB following chemotherapy for patients with refractory myeloid malignancy: chimerism and response.Blood advances · 2020Article
- How I treat relapsed or refractory AML.Blood · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Anna B HalpernClinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington.
Megan OthusPublic Health Sciences Division, Fred Hutchinson Cancer Research Center.
Emily M HuebnerClinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington.
Bart L ScottClinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington.
Paul C HendrieDepartment of Medicine, Division of Hematology, University of Washington.
Mary-Elizabeth M PercivalClinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington.
Pamela S BeckerClinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington.
Heather A SmithSeattle Cancer Care Alliance.
Vivian G OehlerClinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington.
Johnnie J OrozcoClinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington.
Ryan D CassadayClinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington.
Kelda M GardnerDepartment of Medicine, Division of Hematology, University of Washington.
Tara L ChenDeparment of Pharmacy Services, University of Washington.
Sarah A BuckleyHematology/Oncology Fellowship Program, University of Washington/Fred Hutchinson Cancer Research Center.
Kaysey F OrlowskiClinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington.
Asma AnwarHematology/Oncology Fellowship Program, University of Washington/Fred Hutchinson Cancer Research Center.
Elihu H EsteyClinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington.
Roland B WalterClinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington rwalter@fredhutch.org.
Funding
TRAINING IN CANCER BIOLOGY &TRANSPLANTATIONT32CA009515 · NCI · UNIVERSITY OF WASHINGTON · PI NANCY ELLEN DAVIDSON, Effie W Petersdorf · 1985 to 2026
$16.2MRESEARCH TRAINING IN HEMATOLOGYT32HL007093 · NHLBI · UNIVERSITY OF WASHINGTON · PI Janis L Abkowitz · 1985 to 2026
$13.9MNCI NIH HHS T32 CA009515NHLBI NIH HHS T32 HL007093
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedAntineoplastic Combined Chemotherapy ProtocolsCladribineDisease-Free SurvivalFemaleGranulocyte Colony-Stimulating FactorHematologic NeoplasmsHumansLeukemia, Myeloid, AcuteMaleMiddle AgedMitoxantroneSurvival RateCladribineGranulocyte Colony-Stimulating FactorMitoxantrone
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.